Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis)

introduction: genital involvement is observed in approximately 60% of patients with psoriasis, presenting clinicians with formidable challenges in treatment. while new biologic drugs have emerged as safe and effective options for managing psoriasis, their efficacy in challenging-to-treat areas remains inadequately explored. Intriguingly, studies have shown that interleukin (IL)-17 inhibitors exhibit effectiveness in addressing genital psoriasis. objectives: we aimed to determine the effectiveness profile of bimekizumab in patients affected by moderate-to-severe plaque psoriasis with involvement of genitalia. methods: bimekizumab, a dual inhibitor of both IL-17A and IL-17F, was the focus of our 16-week study, demonstrating highly favorable outcomes for patients with genital psoriasis. the effectiveness of bimekizumab was evaluated in terms of improvement in static physician's global assessment of genitalia (sPGA-G) and psoriasis area and severity Index. results: sixty-five adult patients were enrolled. remarkably, 98.4% of our participants achieved a clear sPGA-G score (s-PGA-g=0) within 16 weeks. moreover, consistent improvements were observed in PASI scores, accompanied by a significant reduction in the mean dermatology life quality Index (DLQI), signifying enhanced quality of life. notably, none of the patients reported a severe impairment in their quality of life after 16 weeks of treatment. In our cohort of 65 patients, subgroup analyses unveiled that the effectiveness of bimekizumab remained unaffected by prior exposure to other biologics or by obesity. conclusions: our initial findings suggest that bimekizumab may serve as a valuable treatment option for genital psoriasis. nevertheless, further research with larger sample sizes and longer-term follow-up is imperative to conclusively validate these results.